Monthly Archives: March 2020
Risk of Hepatocellular Carcinoma with Tenofovir vs. Entecavir in Patients with Chronic Hepatitis B
RE: Validation of a Machine Learning Model That Outperforms Clinical Risk Scoring Systems for Upper Gastrointestinal Bleeding
Read the transcript from Dr. Balser’s video message
Hi, everyone. Here’s the latest information on our coronavirus response. The situation is changing by the hour and we will keep you informed as we determine what’s best for our patients — and for all of us at VUMC. Continue reading
Message from Dr. Jeff Balser, President and CEO, about altering our approach to elective care
In order to assure we have the people and the supplies to manage the growing demand, we are altering our approach to what is known as elective care. Continue reading
Effect of gastrointestinal symptoms on patients infected with COVID-19
Prevalence and Clinical Features of Sessile Serrated Polyps: A Systematic Review
Lay summary: In a review of research articles, we found the reported prevalence of sessile serrated polyps to vary based on world region, diagnostic criteria, and examination quality, but there was not much difference among age groups or between sexes. Continue reading
Inflammatory Bowel Disease Clusters Within Affected Sibships in Ashkenazi Jewish Multiplex Families
Clinical and genetic markers of NAFLD and prediction of liver disease mortality. Ready for population screening?
Efficacy of IL12/23 blockade expands our therapeutic targets and challenges the old dogma in ulcerative colitis
Sands et al. expand the therapeutic potential of anti-IL-12/IL-23 blockade in IBD, by demonstrating a clear clinical benefit of ustekinumab as induction and maintenance therapy for ulcerative colitis (UC). The UNIFI trial had a double-blind, placebo-co… Continue reading